ABT stock: buy or sell?
August 23rd, 2019
Should I buy ABT stock?Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. Having a trading strategy helps to make decisions easier, quicker and with less hesitations. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Currently, Abbott Laboratories stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Abbott Laboratories stock a buy?
Banks and financial institutions publish stock ratings everyday.At Stocks2.com, we gathered 15 ratings published for ABT stock in the last 30 days. The general sentiment of these ratings is bullish for ABT stock, with 12 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-8-14||BMO Capital Markets||n/a||n/a|
|2019-7-18||Jefferies Financial Group||n/a||Buy|
|2019-7-18||BMO Capital Markets||n/a||Outperform|
|2019-6-13||Wells Fargo & Co||n/a||Outperform|
|2019-6-13||Bank of America||n/a||Buy|
|2019-4-15||Royal Bank of Canada||n/a||Buy|
|2019-3-14||Wells Fargo & Co||n/a||Buy|
|2019-2-7||Bank of America||Buy||Buy|
ABT stock analysis
Abbott Laboratories eased a terrible -2.89% and closed at $81.93.
Shares of Abbott Laboratories eased a terrible -2.89% and closed at $81.93. ABT is soaring again after a 4.11% correction from its last top on August 13th at $87.10. Since June when ABT stock price broke up the SMA100d line, it gained $6.50 (8.62%). On July/23, ABT hit a new all time high, pushing higher than on Jul/22 tops. Check different trading setups that use ATHs as triggers.
Abbott Laboratories shares eased -3.36% this week, ending at $81.93.
Observing the weekly chart, ABT marked an uptrend of rising tops and rising bottoms. Since its last top late July at $88.76, price slid and bounced up back from $82.31. Breaking down under $82.31 would cancel the current uptrend and it might test lower supports. Note that $88.76 might act as a resistance line. Not so far away is the last all-time high Abbott Laboratories marked late July. Since price and SMA20w lines crossed up early June, ABT climbed $6.08 (8.02%).
ABT stock price history
ABT stock went public on March 17th, 1980 with a price of $0.201. Since then, ABT stock surged a 40,865.00%, with an average of 1,047.80% per year. If you had invested right after ABT's IPO a $1,000 in ABT stock in 1980, it would worth $408,650.00 today.
1: Adjusted price after possible price splits or reverse-splits.
ABT stock historical price chart
ABT stock reached all-time highs on Jul 23rd with a price of $88.76.
ABT stock price target is $90.20How much a stock will be priced tomorrow or next week is quite unpredictable However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. You should not follow the analysts' ABT stock price predictions in the hope that they will be met as they may be wrong and not met. We found 11 price forecasts for Abbott Laboratories stock posted in the last 30 days:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-7-18||Raymond James||Raises Target||$87.00||$93.00||6.9%|
|2019-7-18||Jefferies Financial Group||Raises Target||$80.00||$98.00||22.5%|
|2019-7-18||BMO Capital Markets||Raises Target||n/a||$94.00||-|
|2019-7-16||Morgan Stanley||Raises Target||$85.00||$93.00||9.4%|
|2019-6-13||Wells Fargo & Co||Raises Target||$89.00||$91.00||2.2%|
|2019-6-13||Bank of America||Raises Target||$81.00||$90.00||11.1%|
|2019-4-15||Royal Bank of Canada||Raises Target||n/a||$82.00||-|
|2019-2-7||Bank of America||Reiterates||$73.00||$81.00||11%|
|2019-1-2||Morgan Stanley||Raises Target||$82.00||$85.00||3.7%|
Financials and fundamental analysis
Earnings date and Earnings per ShareSince April, when Abbott Laboratories published its last earnings report, it inched a fine 6.11%. As soon as we get its actual EPS from the earnings report, we will extend this report.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual revenues report draw a great gain of 11.64% to $30,578.00 million dollars. However, its income margin (compared to sales) rose to 7.74%, that is $2,368.00 million. Abbott Laboratories fiscal year ends in December, and to evaluate its evolution since then, we estimate annual sales and income figures by adding results from the last 4 quarters. This is called TTM (or Twelve Trailing Months). So, Abbott Laboratories TTM sales up to March 2019 were $30,723.00 and income $2,622.00 million dollars. When comparing this TTM figures with the last reported annuality, we can esteem Abbott Laboratories business evolution since December 2018: Annual turnover up to March, compared to lastest yearly report, remained constant a neutral 0.47%. Regarding profit margin, Abbott Laboratories stayed steady 0.79% to 7.74%
|2013||$19,660 M||-||$1,970 M10.0%||-|
|2014||$20,247 M||2.99%||$2,284 M11.3%||15.94%|
|2015||$20,405 M||0.78%||$4,423 M21.7%||93.65%|
|2016||$20,853 M||2.20%||$1,400 M6.7%||-68.35%|
|2017||$27,390 M||31.35%||$477 M1.7%||-65.93%|
|2018||$30,578 M||11.64%||$2,368 M7.7%||396.44%|
|TTM||$30,723 M||0.47%||$2,622 M8.5%||10.73%|
Quarterly financial resultsAbbott Laboratories posted $7,535.00 M in revenues for 2019-Q1, a -2.96% decline compared to previous quarter. Reported quarter earnings marked $672.00 M with a profit margin of 8.92%. Profit margin remained stable a 0.50% compared to previous quarter when profit margin was 8.42%. When comparing turnover to same quarter last year, Abbott Laboratories sales marked a slightly good growth and grew a 1.96%.
|2017-Q2||$6,640 M||-||$269 M4.1%||-|
|2017-Q3||$6,830 M||2.86%||$558 M8.2%||107.43%|
|2017-Q4||$7,589 M||11.11%||$-828 M-10.9%||-248.39%|
|2018-Q1||$7,390 M||-2.62%||$418 M5.7%||-150.48%|
|2018-Q2||$7,767 M||5.10%||$733 M9.4%||75.36%|
|2018-Q3||$7,656 M||-1.43%||$563 M7.4%||-23.19%|
|2018-Q4||$7,765 M||1.42%||$654 M8.4%||16.16%|
|2019-Q1||$7,535 M||-2.96%||$672 M8.9%||2.75%|
Abbott Laboratories ownershipWhen you are planning to buy shares of a stock, it's always worth to review its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Abbott Laboratories, 0.72% of all outstanding shares are owned by its staff.
In case of Abbott Laboratories stock, 76.49% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for ABT stock account 0.00%, no big difference from last month.
For a better understanding, the following table shows ownership data compared to other related companies:
|Market cap||$144.2 B||$75.9 B||$57.3 B||$13.4 B||$349.2 B|
|Total shares||1,760.0 M||1,630.0 M||1,390.0 M||268.1 M||2,660.0 M|
|Float shares||1,750.0 M||1,630.0 M||1,390.0 M||266.1 M||2,630.0 M|
|- Institutional holdings (%)||76.5%||75.0%||93.4%||99.7%||69.2%|
|- Insider holdings (%)||0.7%||0.1%||0.2%||0.3%||0.1%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, August 23rd, 2019|
|Day range||$81.36 - $84.25|
|Average true range||$1.87|
|50d mov avg||$85.14|
|100d mov avg||$81.18|
|200d mov avg||$76.80|
Abbott Laboratories performanceTo measure stock performance is always good to compare with competitors or related stocks. We compared Abbott Laboratories against Bristol-Myers Squibb, Boston Scientific, Hologic, , Medtronic, Mylan, Pfizer and Thermo Fisher Scientific in the following table:
|TMOThermo Fisher Sci...||-0.83%||7.00%||15.09%|
Abbott Laboratories competitorsOne check before investing in any stock is to have a look a list of its competitors, in this case for Abbott Laboratories. We chose 8 companies as Abbott Laboratories competitors as they are in the same industry or have similar market objectives.
- Bristol-Myers Squibb (BMY)
- Boston Scientific (BSX)
- Hologic (HOLX)
- Medtronic (MDT)
- Mylan (MYL)
- Pfizer (PFE)
- Thermo Fisher Scientific (TMO)
Latest ABT stock news
- InvestorPlaceAbbott Laboratories Earnings: ABT Stock Surges on Guidance, Q2 BeatJuly 17, 2019
- Seeking AlphaAbbott Laboratories: A Solid Business For An Attractive ValuationMay 8, 2019
- InvestorPlaceAbbott Laboratories Earnings: ABT Stock Down After Q1 BeatApril 17, 2019
- InvestorPlaceAll Signals Are Positive for Buying Abbott LaboratoriesJanuary 22, 2019
- InvestorPlace3 Big Stock Charts for Friday: Incyte, Schlumberger and Abbott LaboratoriesJanuary 4, 2019